NewLimit
Backed by
NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.
Principal/Senior Scientist, mRNA engineering
Principal/Senior Scientist, PK/PD Assays
Executive Recruiter
Executive Assistant
Lead Security & Infrastructure Engineer
Scientist, Functional Genomics
Senior/Research Associate, Functional Genomics
Head of Clinical Development
Computational Biologist
Scientist, Drug Product Analytical
Senior/Research Associate
